Covid19-Sources

Together, our results indicate that Omicron has an increased capability to- suppress IFN production- evade the IFN antiviral stateAs IFNs belong to the innate immune system, this is a kind of immune evasion9/11— Friedemann Weber (@Friedemann1) January 22, 2022

Background: Vaccine effectiveness (VE) against omicron is not well-characterized. We evaluated the effectiveness of two and three doses of BNT162b2 against hosp

BACKGROUND: Waning of COVID-19 vaccine protection and emergence of SARS-CoV-2 Omicron (B.1.1.529) variant have expedited efforts to scale up booster vaccination. This study compared protection afforded by booster doses of the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines, compared to the primary series of only two doses in Qatar, during a large, rapidly growing Omicron wave. METHODS: In a population of 2,232,224 vaccinated persons with at least two doses, two matched, retrospective cohort studies were implemented to investigate effectiveness of booster vaccination against symptomatic SARS-CoV-2 infection and against COVID-19 hospitalization and death, up to January 9, 2022. Association of booster status with infection was estimated using Cox proportional-hazards regression models. RESULTS: For BNT162b2, cumulative symptomatic infection incidence was 2.9% (95% CI: 2.8-3.1%) in the booster-dose cohort and 5.5% (95% CI: 5.3-5.7%) in the primary-series cohort, after 49 days of follow-up. Adjusted hazard ratio for symptomatic infection was 0.50 (95% CI: 0.47-0.53). Booster effectiveness relative to primary series was 50.1% (95% CI: 47.3-52.8%). For mRNA-1273, cumulative symptomatic infection incidence was 1.9% (95% CI: 1.7-2.2%) in the booster-dose cohort and 3.5% (95% CI: 3.2-3.9%) in the primary-series cohort, after 35 days of follow-up. The adjusted hazard ratio for symptomatic infection was 0.49 (95% CI: 0.43-0.57). Booster effectiveness relative to primary series was 50.8% (95% CI: 43.4-57.3%). There were fewer cases of severe COVID-19 in booster-dose cohorts than in primary-series cohorts, but cases of severe COVID-19 were rare in all cohorts. CONCLUSIONS: mRNA booster vaccination is associated with modest effectiveness against symptomatic infection with Omicron. The development of a new generation of vaccines targeting a broad range of variants may be warranted. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement The authors are grateful for institutional salary support from the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, as well as for institutional salary support provided by the Ministry of Public Health, Hamad Medical Corporation, and Sidra Medicine. The authors are also grateful for the Qatar Genome Programme and Qatar University Biomedical Research Center for institutional support for the reagents needed for the viral genome sequencing. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the article. Statements made herein are solely the responsibility of the authors. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Hamad Medical Corporation and Weill Cornell Medicine-Qatar Institutional Review Boards approved this retrospective study with waiver of informed consent. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes The dataset of this study is a property of the Qatar Ministry of Public Health that was provided to the researchers through a restricted-access agreement that prevents sharing the dataset with a third party or publicly. Future access to this dataset can be considered through a direct application for data access to Her Excellency the Minister of Public Health (https://www.moph.gov.qa/english/Pages/default.aspx). Aggregate data are available within the manuscript and its Supplementary information.

The kinetics of the antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) needs to be evaluated since long-term duration of antibody remains largely unknown, particularly in infected healthcare workers (HCW).Prospective study, ...

Es gebe verschiedene Möglichkeiten, wie sich Omikron von einer eher milden Variante in eine stärker krankmachende entwickeln könnte, sagte der Virologe Christian Drosten. Man müsse derzeit befürchten, dass eine Rekombination aus Omikron und Delta passiere, sagte Drosten im Dlf.

Omikron auf dem Vormarsch: Die interaktive Weltkarte zeigt, welche Anteile die Coronavirus-Varianten in welchen Ländern haben.

CovRadar is a tool for the molecular surveillance of the Corona spike protein. The spike protein allows the virus to enter the host cell and is therefore an important target for antibodies and vaccines.

Review this statement about evaluating a patient’s medication regimens for drug-drug interactions before prescribing Paxlovid.

We analyzed the differences in viral environmental stability between the SARS-CoV-2 Wuhan strain and all variants of concern (VOCs). On plastic and skin surfaces, Alpha, Beta, Delta, and Omicron variants exhibited more than two-fold longer survival than the Wuhan strain and maintained infectivity for more than 16 h on skin surfaces. The high environmental stability of these VOCs could increase the risk of contact transmission and contribute to their spread. ### Competing Interest Statement The authors have declared no competing interest.

Stuttgart/Heidelberg – Der Chefpathologe der Uni Heidelberg, Peter Schirmacher, drängt zu viel mehr Obduktionen von Geimpften. Neben Coronatoten müssten auch... #COVID-19 #Impfen

Neurological symptoms highlight the need to understand pathophysiologic mechanisms

Myocarditis (or pericarditis or myopericarditis) from primary COVID19 infection occurred at a rate as high as 450 per million in young males. Young males infected with the virus are up 6 times more likely to develop myocarditis as those who have received the vaccine.

Painful muscles and joints, shortness of breath and lack of energy are all unwanted gifts of a disease that keeps on giving, say researchers. In addition, many victims suffer from post-traumatic stress disorder.

Learn how SARS-CoV-2 infection is categorized by severity of illness.

It is not normal for young athletes to suffer cardiac arrest or death while playing sport, but most of these come shortly after a COVID shot.

Dozens of prominent athletes did not die of heart attacks after COVID-19 vaccination

On Jan 6, 2022, the UK Government's Office of National Statistics (ONS) published their latest report on the prevalence of long COVID in the UK from a representative survey. As of Dec 6, 2021, around 1·266 million people living in the UK had self-reported long COVID (95% CI 1·228–1·304; 2% of the total population), defined as symptoms persisting for more than 4 weeks after the first confirmed or suspected COVID-19 infection. Of these individuals, 892 000 (70%) had confirmed or suspected COVID-19 at least 12 weeks previously.

Viral infections are a common cause of myocarditis. Some studies have indicated an association between COVID-19 and myocarditis.

Long COVID umfasst Symptome, die nach einer akuten COVID-19-Erkrankung neu auftreten und Wochen oder Monate nach Erkrankungsbeginn anhalten. Die Symptome können mit der Zeit abklingen oder sich zu einem anhaltenden Beschwerdebild entwickeln, das mit einer starken Einschränkung der Lebensqualität einhergeht. Eine Subgruppe von Menschen mit Long COVID hat eine große…

Characteristics of people testing positive for COVID-19 from the Coronavirus (COVID-19) Infection Survey.

Results from a study of 19 deceased patients suggests brain damage is a byproduct of a patient’s illness.

This systematic review and meta-analysis investigates the frequency of adverse events in placebo groups compared with that in vaccine groups in COVID-19 vaccine trials.

Are on the rise. But is it Omicron, or "Omicron"?

3/4 der Impfreaktionen/Nebenwirkungen eingebildet?Laut einer Untersuchung der Harvard Uni sind bis zu 76% der den Körper betreffenden Reaktionen nach Erst-Impfung und 52% der gemeldeten Folgen nach der 2. Impfdosis dem sogenannten „Nozebo“ (analog Plazebo) Effekt zuzuschreiben! pic.twitter.com/eoaKdIlxxu— OrthopaeDenker (@dokhollidays) January 20, 2022

Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001 that successfully met both co-primary endpoints. Superio

In the summer of 2021, European governments removed most NPIs after experiencing prolonged second and third waves of the COVID-19 pandemic. Most count…

The new SARS-CoV-2 variant of concern “Omicron” was recently (Nov. 24th. 2021) spotted in South Africa and already spread around the world due to its enhanced transmissibility. The variant became conspicuous as it harbors more than thirty mutations in the spike protein with 15 mutations in the RBD region alone, potentially dampening the potency of therapeutic antibodies and enhancing the ACE2 binding. More worrying, Omicron infections have been reported in individuals who have received vaccines jabs in South Africa and Hong Kong. Here, we investigated the binding strength of Omicron with ACE2 and seven monoclonal antibodies that are either approved by FDA for COVID-19 therapy or undergoing phase III clinical trials. Computational mutagenesis and binding free energies could confirm that Omicron Spike binds ACE2 stronger than prototype SARS-CoV-2. Notably, three substitutions, i.e., T478K, Q493K, and Q498R, significantly contribute to the binding energies and doubled electrostatic potential of the RBDOmic-ACE2 complex. Instead of E484K substitution that helped neutralization escape of Beta, Gamma, and Mu variants, Omicron harbors E484A substitution. Together, T478K, Q493K, Q498R, and E484A substitutions contribute to a significant drop in the electrostatic potential energies between RBDOmic-mAbs, particularly in Etesevimab, Bamlanivimab, and CT-p59. CDR diversification could help regain the neutralization strength of these antibodies; however, we could not conduct this analysis to this end. Conclusively, our findings suggest that Omicron binds ACE2 with greater affinity, enhancing its infectivity and transmissibility. Mutations in the Spike are prudently devised by the virus that enhances the receptor binding and weakens the mAbs binding to escape the immune response. ### Competing Interest Statement The authors have declared no competing interest.

Ich danke allen, die sich dafür einsetzen, dass wir mehr über #LongCovid und #PostCovid erfahren!Auch wenn wir noch nicht genau wissen in welcher Häufigkeit mit #Langzeitfolgen zu rechnen ist:Wir müssen wohl auch bei Kindern von 2% ausgehen!https://t.co/1NvJgKodWo👇 pic.twitter.com/3ISRAEitTz— Amelie Thobaben (@AThobaben) August 17, 2021

Prophezeiungen, Prognosen, Vorhersagungen und Zukunftsgedanken der Querdenker ab September 2021 mit Bodo Schiffmann, Michael Ballweg, Attila Hildmann, ...

This report has been published to share the detailed variant surveillance analyses which contribute to the variant risk assessments and designation of new variants of concern (VOC) and variants under investigation (VUI). This specialist technical briefing contains early data and analysis on emerging variants and findings have a high level of uncertainty.